NCT01731652已完成2 期
Phase II Pilot Study With TMX 101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 12
- 试验地点
- 4
- 主要终点
- To assess the activity of TMX-101, as determined by the number of patients who experience complete response (CR).
研究概览
简要总结
This is a Phase II pilot study to explore the effect of intravesical TMX-101 in patients with CIS bladder cancer, as assessed by histology and cytology after TMX-101 treatment.
详细描述
This study is an open label, pilot study of TMX-101 in the treatment of carcinoma in situ. TMX-101 is a new formulation of Imiquimod optimized for intravesical delivery. Imiquimod possesses immune-stimulatory properties. TMX-101 is being developed as a potential treatment for patients with non-invasive bladder cancer, including patients with CIS bladder cancer.
Following confirmation of CIS by histology, patients will receive weekly instillations of TMX-101 for 6 weeks. Five to seven weeks after the last instillation, biopsies and cytology will be performed. Response to treatment will be determined based on cytology and tissue sample histology findings.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Males or female patient is aged ≥18 years.
- •Pathologically-proven, recurrent, primary, secondary or concomitant carcinoma in situ disease, defined by having either Ta or T1 with CIS, or CIS alone. In cases with T1 tumor lesions, muscularis propria tissue should be in the resected specimen to confirm that it is tumor-free.
- •Patient has undergone mapping of the bladder between Days -28 and -14, with at least one biopsy providing pathological confirmation of CIS of the bladder. Slides must be available for a central pathology review.
- •Patient has undergone bladder washing for cytology between Days -28 and -
- •In patients in whom Ta or T1 lesion(s) were resected, the bladder washing must have occurred after the resection. Slides must be available for a central cytology review.
- •Patient has an ECOG performance status 0-
- •Patient has adequate bone marrow, hepatic, and renal function within 4 weeks before Day
- •Patient has read and understood the informed consent form and is willing and able to give informed consent.
- •Patient fully understands the requirements of the study and is willing to comply with all study visits and assessments.
- •If a woman of childbearing potential (WCBP), patient has a negative blood pregnancy test at the Screening visit. For the purposes of this study, WCBP is defined as a post-pubescent female, unless post-menopausal for at least 2 years, surgically sterile, or sexually inactive.
- •If patient is a WCPB or male patient with a female partner of childbearing potential, must be willing to avoid pregnancy by using an adequate method of contraception from 2 weeks before through 4 weeks after the last study drug treatment. Adequate contraception is defined as follows: 2 barrier methods or 1 barrier method with a spermicide or intrauterine device.
排除标准
- •Patient has evidence of muscle-invasive disease (i.e., T2 or higher)
- •In the Investigator's opinion, patient is not able to hold instillation for at least 1 hour.
- •In the Investigator's opinion, patient cannot tolerate intravesical administration or intravesical surgical manipulation.
- •Patient has received radiation therapy of pelvis within 12 months before the first study drug treatment.
- •Patient requires perioperative intravesical chemotherapy.
- •Patient has a history of malignancy of the upper urinary tract.
- •Patient has bone marrow impairment as evidenced by:
- •Hemoglobin <9.0 g/dL
- •Absolute neutrophil count (ANC) <1.5×109/L
- •Platelet count <120×109/L.
- •Patient has renal impairment, as evidenced by:
- •Serum creatinine >2× the upper limit of normal (ULN), and/or
- •Calculated creatinine clearance <40 mL/min.
- •Patient has liver function abnormality, as evidenced by:
- •Total bilirubin >1.5×ULN, or
- •Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) >2.5×ULN.
- •Patient has a bleeding disorder, as evidenced by an international normalized ratio (INR) >1.5×ULN.
- •Patient is known to be positive for human immunodeficiency virus (HIV) or has active hepatitis B or C infection.
- •Patient has a clinically significant active infection at the time of the first study drug treatment.
- •Patient has any medical or psychiatric condition that, in the Investigator's opinion, might impair the patient's well-being or preclude adherence to the protocol or completing the study as per protocol.
- •Patient has suspected hypersensitivity to imidazoquinoline compounds, poloxamer 407, hydroxy propyl betacyclodextrin, or lactic acid.
- •If female, patient is pregnant or breast feeding.
- •Patient participated in any other protocol involving administration of an investigational agent within 3 months before Day 0.
研究组 & 干预措施
TMX-101
Experimental
TMX-101 0.4% (200 mg in 50 ml) instilled in the bladder once weekly for 6 weeks
干预措施: TMX-101 (Drug)
结局指标
主要结局
To assess the activity of TMX-101, as determined by the number of patients who experience complete response (CR).
时间窗: 5 to 7 weeks after the last TMX -101 instillation
次要结局
- Proportion of patients experiencing adverse events (AEs), including serious adverse events (SAEs) and AEs leading to discontinuation from the study.(Patients will be followed through treatment and follow-up, for an expected total period of up to 13 weeks.)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
1 期
VPM1002BC in Recurrent Non-muscle Invasive Bladder CancerBladder CancerNCT02371447Swiss Group for Clinical Cancer Research39
终止
2 期
Multiple-Dose Study to Evaluate the Safety and Efficacy of IXT-m200Methamphetamine-dependenceMethamphetamine AbuseNCT05034874InterveXion Therapeutics, LLC61
进行中（未招募）
1 期
Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the BladderUrothelial Carcinoma of the Urinary BladderNCT02202772Guarionex J. Decastro51
进行中（未招募）
1 期
Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG TreatmentUrinary Bladder NeoplasmsImmunotherapyNCT04706598Fudan University25
已完成
2 期
A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM)Glioblastoma MultiformeNCT01280552Precision Life Sciences Group124